REVIEW

An updated overview on the development of new photosensitizers for anticancer photodynamic therapy

Juan Zhang\textsuperscript{a,b,†}, Chengshi Jiang\textsuperscript{a,‡}, João Paulo Figueiró Longo\textsuperscript{b}, Ricardo Bentes Azevedo\textsuperscript{b}, Hua Zhang\textsuperscript{a,∗}, Luis Alexandre Muehlmann\textsuperscript{b,c,*}

\textsuperscript{a}School of Biological Science and Technology, University of Jinan, Jinan 250022, China
\textsuperscript{b}Institute of Biological Sciences, University of Brasilia, Brasilia 70910-900, Brazil
\textsuperscript{c}Faculty of Ceilandia, University of Brasilia, Brasilia 72220-900, Brazil

Received 31 May 2017; received in revised form 14 July 2017; accepted 15 July 2017

KEY WORDS
Anti-cancer; Photosensitizers; Photodynamic therapy; Photochemical reactions; Oncology; BODIPY

Abstract Photodynamic therapy (PDT), based on the photoactivation of photosensitizers (PSs), has become a well-studied therapy for cancer. Photofrin\textsuperscript{®}, belonging to the first generation of PS, is still widely used for the treatment of different kinds of cancers; however, it has several drawbacks that significantly limit its general clinical use. Consequently, there has been extensive research on the design of PS molecules with optimized pharmaceutical properties, with aiming of overcoming the disadvantages of traditional PS, such as poor chemical purity, long half-life, excessive accumulation into the skin, and low attenuation coefficients. The rational design of novel PS with desirable properties has attracted considerable research in the pharmaceutical field. This review presents an overview on the classical photosensitizers and the most significant recent advances in the development of PS with regard to their potential application in oncology.

© 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Cancer is among the leading causes of morbidity and mortality worldwide. In 2012, approximately 14 million cancer cases were newly diagnosed, and the number of cancer-related deaths was 8.2 million, which is projected to rise by about 70% over the next two decades. Currently, clinical treatments for cancer include surgery, radiation therapy, chemotherapy and, more recently, immunotherapy and other small-molecule targeted therapies, along with a combination of these strategies. However, these treatments present some important drawbacks. For instance, traditional chemotherapy, as it interferes in cell division, is often associated with severe systemic adverse effects, such as myelosuppression, mucositis, alopecia, and others. Also, surgical resection of certain tumors cannot avoid a high recurrence rate, while the cumulative radiation dose extremely limits the radiotherapy. Thus, although refinement of the conventional anticancer therapy is important, development of new treatment approaches that are safe, potent, and cost-effective seems especially urgent.

2. Photodynamic therapy

2.1. An accidental finding for cancer treatment

In the 1890s, Raab accidentally found that the irradiation with visible light was lethal to paramecia previously exposed to acridine, and postulated that the transfer of light energy to the acridine red was the crucial event behind the cytotoxicity observed in paramecia and that this effect was related to the fluorescence of the dye. Then the first clinical observation of PDT with oral eosin to treat epilepsy was reported by the neurologist Jean Prime in 1900. Later, von Tappeiner and Jesionek proposed the use of topical eosin with light exposure to treat skin tumors. This was the first published report on the use of PDT to treat tumors in human patients. Subsequently, von Tappeiner observed that O2 was an important component of the events found by Raab, and coined the term “photodynamic action”.

The study of the anticancer potential of PDT was conducted by few researchers up to the 1950s when the interest in this field began to increase. The publication of some seminal reports on the use of porphyrins as both PSs and fluorescence diagnostic tools in the 1950s and 1960s was followed by a series of works on the anticancer activity of PDT against different tumors. Mainly over the last three decades, several types of PSs have been developed and applied in preclinical and clinical trials; some of these molecules reached the market and have shown to be effective against different kinds of cancers. The main advantage of PDT over conventional anticancer therapies is the ability to limit toxic effects to the biological tissues exposed to both the PS and light, thus protecting normal tissues.

In addition, PDT has also been used successfully against non-malignant disorders in diverse fields, such as urology, immunology, ophthalmology, dentistry, dermatology and others.

2.2. Photodynamic therapy mechanisms

PDT is based on the excitation of PS with light at specific wavelengths, culminating in type I and type II photochemical reactions. As shown in Fig. 1, a PS can be activated from its ground state to a short-lived excited singlet state (PS1) by light. Then, either the excited PS may decay back to the ground state by emitting fluorescence, or it can undergo intersystem crossing whereby the spin of its excited electron inverts to form a relatively long-lived triplet state (PS3). The triplet excited PS can also decay back to the ground state by emitting phosphorescence, but most importantly it can directly interact with surrounding substrates (e.g., cell membrane or other biomolecules) to form radicals, which then react with O2 to produce reactive oxygen species (ROS), such as superoxide anion radicals (O2·−), hydroxyl radicals (·OH), and hydrogen peroxides (H2O2, type I reaction). Alternatively, the energy of the excited PS can be directly transferred to O2 (itself a triplet in the ground state) to form 1O2 (type II reaction). It is worth noting that both type I and type II reactions can occur simultaneously, and the ratio between these processes is affected by the nature of the PS, as well as by the concentrations of O2 and other substrates. However, most of the experimental studies indicate that the photoactivated production of 1O2, namely type II reaction, plays a dominant role in in vivo PDT.

In a biological medium the reactive species generated by the photodynamic process can react with a large number of biomolecules, mainly proteins, nucleic acids, and lipids. The damage to biomolecules may (i) irreversibly damage tumor cells resulting in necrosis, apoptosis, or autophagy, (ii) cause tumor ischemia following PDT-induced vascular injury, and (iii) activate the immune response against tumor antigens. Therefore, the main downstream targets of PDT include tumor cells, as well as tumor-associated microvasculature, and, indirectly, the host immune system. Moreover, the combination of PDT with other chemotherapeutic drugs may help to achieve a long-term tumor control, due to their possible synergistic effects resulting from the combination of downstream responses in PDT and the mechanisms of chemotherapeutic drugs.

3. The photosensitizers for anticancer PDT

3.1. First generation PSs

Hematoporphyrin (Hp), a complex mixture of porphyrinic compounds, was the first porphyrin used as PS. The purification and chemical modification of Hp led to the discovery of a
hematoporphyrin derivative (HpD), which was shown to be more selective for tumor tissues, inducing a less intense skin photosensitization in comparison to Hp. Later, a mixture of porphyrin dimers and oligomers isolated from HpD was marketed as Photofrin. Despite Photofrin was widely used for treating different cancers, the clinical use was limited by its intrinsic drawbacks, including I) poor chemical purity with a mixture of more than 60 molecules; II) its long half-life and intense accumulation in the skin, responsible for the induction of a prolonged skin photosensitization, which sometimes persists for 2 or even 3 months after Photofrin administration; III) its low molar attenuation coefficient (1.17 × 10^3 mol/L · cm); and IV) its activation wavelengths being too short for a good tissue penetration.

3.2. Second generation PSs

The disadvantages associated with first generation PSs have led to extensive investigation aimed at improving the efficacy of PS molecules via alteration of the peripheral functionality of the porphyrin, or direct modification of the porphyrin core. The following seminal works on the first generation PS have resulted in the production of several new non-porphyrinoid PS molecules (Fig. 2). These have been developed over the decades, including metalloporphyrins (Lutrin® and Lutex®), porphycenes, phco- phorhins (Tookad®), purpurins (Purlytin®), phthalocyanines, chlorins (Foscan®), protoporphyrin IX precursors (Hexvix®, MetVix® and Levulan®), phenoanthazones (methylene blue, and toluidine blue), cyanines (merocyanine 540), dipyrromethenes, hypericin and xanthenes (Rose Bengal).

3.3. Strategies for designing new generation PSs

Despite the extensive research performed to develop new and improved PSs, only a few second generation PSs, such as Levulan®, MetVix®, Photoclog® and NPe6, have been approved for the clinical treatment of cancer. The rational design of novel PS with desirable properties remains a big challenge for the pharmaceutical industry. The latest review article related to the design of PSs for photodynamic therapy, authored by Garland et al., dates back to 2009. As stated before, the overall success of PDT mainly depends on the 1O2 yield, molecule stability, the penetration depth of absorbed light and distribution of PSs, so that:

1) The 1O2 generated in type II photoreaction is a key factor for PDT, since it is considered as the major cytotoxic species in PDT. Generally, the introduction of heavy atoms (such as Br, and I) into the PS molecule or inhibition of the interaction between triplet excited PS and native free radicals can increase the 1O2 production;
2) A disadvantage of many of the current PSs is their tendency to aggregate, resulting in short triplet state lifetimes and decreased 1O2 yields. Therefore, a structural modification that can suppress the aggregation tendency of a PS should be considered carefully to improve the property of PS. Usually, the presence of a central metal ion and the number of charges in the molecule will have an important role for the stability of PSs;
3) The increased energy of light of longer wavelength is also a major motivation for the development of new PSs. Generally, expanding the molecular conjugate system by introducing an electron-rich donor can improve the PS absorption efficiency of red light, and enhance the penetration of light into human tissue;
4) Improving the target distribution of PS is also very important to increase its efficacy and reduce adverse effects. The ligand-mediated targeting strategy in PDT has been explored. Herein, the targeted ligands, such as biotin, folate, peptide, etc., were frequently used for delivery of PS to cancer tissues;
5) In addition, the positions and types of the substituent groups on the molecule can influence the lipophilicity of the molecule, which further influences the tissue location of PS.

4. Recent development in anticancer PSs

A literature survey indicates that there are quite a lot of review articles about PSs and PDT, but few of them specifically focus on the discovery and development of new PSs as anticancer agents. With the rapid development in PS research area, a number of new, more potent and tumor-specific PSs showing promising clinic potential have been investigated. Herein, this section summarizes the recently reported PSs mainly focusing on porphyrin, chlorin, phthalocyanine and BODIPY derivatives, aiming to provide a better understanding of the factors affecting the efficacy of PS molecules.

4.1. Porphyrin-type PSs

The porphyrin macrocycles were mainly developed and clinically used in the last few decades. Side-chains containing functional groups, such as nitrogen atoms, carboxylic acid, and sugar, are frequently incorporated into the porphyrin skeleton. For example, a novel porphyrin-based PS (5,10,15,20-tetrakis[5-diethylamino]pentyl) porphyrin, TDPP, I) with four diethylaminopropyl side-chains recently reported by Li et al. showed a high 1O2 yield with the ability to kill human esophageal cancer cell lines (Eca-109) and significantly reduce the growth of Eca-109 xenograft tumors in BABL/c nude mice. Among a series of β-alkylaminoporphyirins reported later by Chen’s group, derivative 2 showed higher phototoxicity than Hp monomethyl ether and the lowest toxicity in the dark. Another new porphyrin derivative 3 bearing ethylenediaminetetraacetic acid showed intense in vitro phototoxicity on HepG2 and BGC823 cell lines, and further inhibited the growth of BGC823 tumors in nude mice. Mechanism studies indicated that 3 can induce cell death via the mitochondrial apoptotic pathway mainly triggered by lysosomal photodamage. Costa et al. recently reported a hydrophobic porphyrin derivative 4 bearing four isoquinoline moieties, which showed a high quantum yield of 1O2 generation, the absence of toxicity in the dark, and significant in vitro phototoxicity against HT29 cells with an IC50 in the micromolar range.
Horiuchi and co-workers\textsuperscript{77} studied the effect of a silyl group on the photodynamic properties of tetraphenylporphyrin derivative 5. The results indicated that silylation could lead to an improvement in the quantum yield of $^{1}\text{O}_2$ sensitization for derivatives. In addition, there has been recent growth in interest in the preparation of metal-porphyrin conjugates as potential photocytotoxic agents. The porphyrins functionalized with Pt\textsuperscript{II} were the first metal-porphyrin derivatives developed for biomedical application\textsuperscript{78}. Later, examples related to other metal-porphyrin conjugates have been described. For example, the glucopyranoside-conjugated porphyrin 6 bearing In\textsuperscript{3+} synthesized by Nakai et al.\textsuperscript{75} exhibited strong phototoxicity, correlating with its high abilities of $^{1}\text{O}_2$ yield and cell permeability. Another Re-porphyrin conjugate 7, bearing four [1,4,7]-triazacyclononane units prepared by Mion et al.\textsuperscript{79}, showed remarkable phototoxicity on Hela cells with non-toxicity in the dark (Fig. 3).

4.2. Chlorin-type PSs

Compared with porphyrins, chlorin-type PSs attracted considerable attention due to their intense absorption in relatively harmless NIR region, which can penetrate deeply into biological tissues. However, the development of chlorin derivatives was significantly limited by their poor water solubility. Therefore, chlorin-type PSs have been modified by conjugation with amino acids, peptides, and sugars to improve their solubility for PDT investigations. For example, Meng et al.\textsuperscript{80} prepared a series of chlorin P\textsubscript{6}-based water-soluble amino acid conjugates. Among these synthetic derivatives, compound 8 showed strong absorption in the phototherapeutic window, relatively high $^{1}\text{O}_2$ quantum yield, and high phototoxicity against melanoma cells with low toxicity in the dark. Also, compound 8 exhibited better \textit{in vivo} PDT antitumor efficacy than verteporfin on mice bearing B16F10 tumors. Another photocytotoxic chlorin $\text{e}_6$ bis(amiino acid) conjugate 9 bearing two different amino acids, lysine at 13 and aspartate at 15 was regioselectively synthesized by Smith and co-workers\textsuperscript{81}. A water-soluble chlorin derivative 10, which was surrounded by four perfluorinated aromatic rings and conjugated with maltotriose (MaI\textsubscript{3}) molecules, showed excellent biocompatibility, strong photosorption in the longer wavelength regions and high photocytotoxicity\textsuperscript{82}.

The use of boron-containing substances in the treatment of cancer has received a great deal of attention due to their high probability of producing particles and lithium-7 nuclei\textsuperscript{83}. Boron-containing chlorin derivatives have also been explored in PDT applications\textsuperscript{84}. Recently, a new chlorin derivative 11 containing phenylboronic acid moieties was synthesized by Tai and co-workers\textsuperscript{84}. This compound could significantly inhibit tumor growth \textit{in vivo} and showed rapid clearance from normal tissues. To improve the cell permeability of chlorin-type PSs, Gushchina et al.\textsuperscript{85} introduced hydrophobic carbon chains into chlorin $\text{e}_6$ to yield a series of new amide derivatives 12, which exhibited good photoactivity and low toxicity in the dark against P388 and K562 cancer cells. Chlorin and bacteriochlorin derivatives 13\textsuperscript{86} bearing chloro-5-sulfophenyl fragments showed promising phototherapeutic properties, such as high water solubility, high photostability, high $^{1}\text{O}_2$ quantum yields and negligible dark cytotoxicity. Patel et al.\textsuperscript{87} recently reported an \textit{NIR} bacteriochlorin analogue 14 to be

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure_3.png}
\caption{Chemical structures of porphyrin-type PSs 1–7.}
\end{figure}
a promising dual-function agent for fluorescence-guided surgery with an option for treating cancer in PDT. This compound exhibited higher tumor uptake and long-term cure in BALB/c mice bearing Colon 26 tumors. Most of all, it showed low skin phototoxicity, which provides a significant advantage over the clinically approved HD as well as other porphyrin-based PSs (Fig. 4).

4.3. Phthalocyanine-type PSs

Phthalocyanine derivatives were shown to be most promising PSs. However, the low solubility and π-π stacking in these molecules limited their further clinical application. Strategies to overcome these disadvantages can involve incorporations of cationic or anionic groups, peptides, β-cyclodextrins, crown ethers, glycerinum and so on. Recently, 2-(morpholin-4-yl)ethoxy-substituted phthalocyanine \( \text{15} \) was synthesized by Kucinska et al. Biological test results indicated that \( \text{15} \) showed potent cytotoxicity against PC3 and A375 under irradiation, while its cytotoxicity in the dark was very low. Another novel Mg(II)-phthalocyanine \( \text{16} \), bearing (2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy substituent at a non-peripheral position, was found to show strong photocytotoxicity at 1 mol/L with 100% photokilling of the human oral squamous cell carcinoma cell lines, HSC-3.

The development of multifunctional molecules has also been considered for overcoming drug resistance and low therapeutic efficacy. For example, Zhou et al. reported a derivative \( \text{17} \) bearing a cytostatic coumarin moiety, zinc(II) phthalocyanine and a tri(ethyleneglycol) linkage showed dual photodynamic and chemotherapeutic activities. These conjugates exhibit high photocytotoxicity against HepG2 cells (IC\( _{50} \) ≈ 14–44 nmol/L), low aggregation tendency and high cellular uptake. Other similar examples are the phthalocyanine-8-hydroxyquinoline conjugates \( \text{18} \). Ranyuk et al. reported a series of water-soluble zinc phthalocyanine-peptide conjugates \( \text{19} \), which targeted the gastrin-releasing peptide receptor. Novel far-red-absorbing Zn(II) phthalocyanine derivative \( \text{20} \) bearing [(triethylammonio)ethyl]sulfanyl substituents in the peripheral or nonperipheral positions were synthesized by Machacek et al. The bioassay results indicated that the Zn complex exhibited photocytotoxicity against 3T3, Hela, SK-MEL-28, and HCT116 cancer cell with IC\( _{50} \) values in a submicromolar range, and low toxicity in the dark (TC\( _{50} \) ≈ 1500 mol/L). Shen et al. reported a series of first silicon(IV) phthalocyanine nucleoside (uridine, 5-methyluridine, cytidine, and 5-N-cytidine) conjugates. Among them, the uridine-containing complex \( \text{21} \) exhibited the highest photocytotoxicity against HepG2 cells (IC\( _{50} \) = 6 nmol/L), with high cellular uptake and non-aggregated nature in the biological media. Bio et al. developed a multifunctional prodrug \( \text{22} \) composed with Si phthalocyanine, a SOL-labile aminoacyl linker and the cytotoxic drug combretastatin A-4 (CA4). Once illuminated, \( \text{22} \) showed improved toxicity, but reduced toxicity in the dark compared with CA4 (Fig. 5).

4.4. BODIPY-type PSs

Another promising class of PS suitable for PDT is the distyryl boron dipyrromethene (BODIPY) dyes, which have proven to be a valuable family of compounds with diverse applications rivaling that of porphyrin. The BODIPY PSs are equipped with heavy halogen atoms, such as Br and I, in the organic chromophore to make compounds reach the triplet excited state by quenching the fluorescence and facilitating intersystem crossing. Erbas-Cakmak et al. designed a water-soluble pH and GSH responsive distyryl-BODIPY PS \( \text{23} \), which could be activated by protonation at neutral pH and reductive cleavage of the disulfide linker at elevated GSH concentration. Recently, Lo and

Figure 4 Chemical structures of chlorin-type PSs 8–14.
coworkers\textsuperscript{103} reported another new class of pH/thiol responsive BODPY PSs that contained either the ketal or disulfide linker. Noteworthy, the unsymmetrical complex 24 exhibited the greatest enhancement in the $^1$O$_2$ generation and fluorescence intensity upon activation, which was considered to be a promising theranostic agent for targeted imaging and PDT of cancer. Platinum (II) complex 25 synthesized by Mitra et al.\textsuperscript{104} could achieve mitochondrial-targeted photocytotoxicity via disruption of the mitochondrial membrane potential and apoptosis. This complex generated excellent photocytotoxicity against HaCaT cells but remained non-toxic in the dark (IC$_{50}$ > 100 mol/L). A novel photoactivatable bichromophoric conjugate 26 was developed by Fraix and coworkers\textsuperscript{105}. This compound combined BODIPY and aniline derivative as nitric oxide photodonor, which had an amplified photomortality on melanoma cancer cells. Lincoln et al.\textsuperscript{106} prepared two small meso-acetoxymethyl BODIPY dyes 27, which showed improved photostability against singlet oxygen compared to the BODIPY PSs lacking the acetoxymethyl group. Compounds 27 can readily embed in the lipid membranes of Hela cells and efficiently induced light-dependent apoptosis at nanomolar concentration. An orthogonal BODIPY trimer 28 without halogen atom substituent was shown to have strong absorption in the visible region and high $^1$O$_2$ generation capability\textsuperscript{107} (Fig. 6).

5. Conclusions

The discovery of novel PS molecules with desired pharmaceutical properties and the application of novel PS in clinical trials are challenging tasks. During the last several years, most research work is based on the modification and optimization of old-style PSs. Therefore, molecules considered as the second generation PS mainly have been derived from porphyrin and porphyrin-related structures. The most recent activity in the PS field for PDT of cancer has been considerable, and the design of non-porphyrin PSs, which possess shorter periods of photosensitization, longer activation wavelengths and higher singlet oxygen yield, still attracts more attention in the field of anticancer PDT.

Additional to the synthesis of new types of PS molecules, the association of classical PSs to different carriers has also been explored to improve their photophysical properties and/or their targeting to tumors. On one hand, antibodies, receptor ligands, and other targeting molecules have been used to actively increase the accumulation of PSs in tumors. On the other hand, different nanostructures have been used to enhance or to maintain the activity of PSs in aqueous media, and to actively and/or passively deliver these molecules to tumors. Both of these systems, and even combinations of them, have been referred to as the third generation PS, and some encouraging results have been reported in the literature regarding the use of this strategy in anticancer PDT. With the significant successes on the developments of new PSs for PDT, it is expected that PDT will gain more widespread use in clinical practice.

Acknowledgments

This work was financially supported by the National Natural Science Foundation of China (No. 21672082), Shandong Key Development Project (No. 2016GSF201209), Young Taishan Scholars Program.

Figure 5 Chemical structures of phthalocyanine-type PSs 15–22.
Review on new photosensitizers for anticancer photodynamic therapy

Figure 6 Chemical structures of BODIPY-type PSs 23–28.

Figure 6 Chemical structures of BODIPY-type PSs 23–28.

References

1. World Health Organization. Cancer. [Cited 30 March 2017]. Available from: <http://www.who.int/mediacentre/factsheets/fs297/en/>.

2. Lucky SS, Soo KC, Zhang Y. Nanoparticles in photodynamic therapy. *Chem Rev* 2015;115:1990–2042.

3. De Angelis C. Side effects related to systemic cancer treatment: are we changing the Promethean experience with molecularly targeted therapies?. *Curr Oncol* 2008;15:198–9.

4. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. *Transl Lung Cancer Res* 2014;3:242–9.

5. Liu G, Zhang S, Ma Y, Wang Q, Chen X, Zhang L, et al. Effects of error on dose of target region and organs at risk in treating nasopharynx cancer with intensity modulated radiation therapy. *Pak J Med Sci* 2016;32:95–100.

6. Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. *Z Biol* 1900;39:524–46.

7. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. *Photochem Photobiol* 2001;74:656–69.

8. Primel. *Des Accidents Toxiques Produit par l’Eosinate se Sodium*. 2nd ed. Paris: Jouve et Boyer; 1900.

9. Von Tappeiner H, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. *Munich Med Wochenschr* 1903;47:2042–4.

10. Tappeiner H, Jodbauer A. Uber die Wirkung der photodynamischen (fluoreszierenden) Stoffe auf Infusorien. *Dtisch Arch Klin Med* 1904;80:427–87.

11. Lipson RL, Baldes EJ, Olsen AM. The use of a derivative of hematoporphyrin in tumor detection. *J Natl Cancer Inst* 1961;26:1–11.

12. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. *Cancer Res* 1978;38:2628–35.

13. Lovell JF, Liu TWB, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. *Chem Rev* 2010;110:2839–57.

14. Cerman E, Cekic O. Clinical use of photodynamic therapy in ocular tumors. *Surv Ophthalmol* 2015;60:557–74.

15. Benov L. Photodynamic therapy: current status and future directions. *Med Prin Pract* 2015;24:14–28.

16. Bozzini G, Colin P, Betrouni N, Nevoux P, Ouzzane A, Puech P, et al. Photodynamic therapy in urology: what can we do now and where are we heading?. *Photodiagn Photodyn Ther* 2012;9:261–73.

17. Cotter TG. Apoptosis and cancer: the genesis of a research field. *Nat Rev Cancer* 2009;9:501–7.

18. Silva JN, Filipe P, Morlire P, Maziere JC, Freitas JP, Gomes MM, et al. Photodynamic therapy: dermatology and ophthalmology as main fields of current applications in clinic. *Biomed Mater Eng* 2008;18:319–27.

19. Konopka K, Goslinski T. Photodynamic therapy in dentistry. *J Dent Res* 2007;86:694–707.

20. Bablas P, Schreml S, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology: state-of-the-art. *Photodermatol Photoimmunol Photomed* 2010;26:118–32.

21. Ding HY, Yu HJ, Dong Y, Tian RH, Huang G, Boothman DA, et al. Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia. *J Control Release* 2011;156:276–80.

22. Shah J, Park S, Aglyamov S, Larson T, Ma L, Sokolov K, et al. Photoacoustic imaging and temperature measurement for photothermal cancer therapy. *J Biomed Opt* 2008;13:034024.

23. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. *J Natl Cancer Inst* 1998;90:889–905.

24. Solban N, Rizvi I, Hasan T. Targeted photodynamic therapy. *Lasers Surg Med* 2006;38:522–31.
25. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. *Nat Rev Cancer* 2003;3:380–7.
26. Longo JPF, Muehlmann LA, Miranda-Vilela AL, Portilho FA, De Souza LR, Silva JR, et al. Prevention of distant lung metastasis after photodynamic therapy application in a breast cancer tumor model. *J Biomed Nanotechnol* 2016;12:689–99.
27. Castano AP, Mroz P, Wu MX, Hamblin MR. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. *Proc Natl Acad Sci U S A* 2008;105:5495–500.
28. Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. *J Natl Cancer Inst* 1975;55:115–21.
29. Juzeniene A, Peng Q, Moan J. Milestones in the development of photodynamic therapy and fluorescence diagnosis. *Photochem Photobiol Sci* 2007;6:1234–45.
30. Triesscheijn M, Baas P, Schellens JHM, Stewart FA. Photodynamic therapy in oncology. *Oncologist* 2006;11:1034–44.
31. Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AB, Dougherty TJ. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (photochlor) and 5-ALA-induced protoporphyrin IX. *Lasers Surg Med* 2006;38:439–49.
32. Sharman WM, Allen CM, Van Lier JE. Photodynamic therapeuticss: basic principles and clinical applications. *Drug Discov Today* 1999;4:507–17.
33. Josefsen LB, Boyle RW. Photodynamic therapy: novel third-generation photosensitizers one step closer?. *Br J Pharmacol* 2008;154:1–3.
34. Wall Jr MH, Basu P, Buranda T, Wicks BS, Findsen EW, Ondrias M, et al. Photoinduced electron transfer in covalently linked oxomolybdenum(V) porphyrin systems. *Inorg Chem* 1997;36:5676–7.
35. Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. *Semin Cancer Biol* 2006;16:466–76.
36. Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler Dougherty TJ. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (photochlor) and 5-ALA-induced protoporphyrin IX. *Lasers Surg Med* 2006;38:439–49.
37. Vogel E, Köcher M, Schmickler H, Lex J. Porphycene-α novel porphin isomer. *Angew Chem Int Ed* 1986;25:257–9.
38. Guardiano M, Biolo R, Jori G, Schaffner K. Tetra-s-propylporphycene as a tumour localizer: pharmacokinetic and phototherapeutic studies in mice. *Cancer Lett* 1989;44:1–6.
39. Trachtenberg J, Weersink RA, Davidson SRH, Haider MA, Bogards A, Gertner MR, et al. Vascular-targeted photodynamic therapy (pseudoporphyrin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. *BJU Int* 2008;102:556–62.
40. Taneka SS, Bennett J, Coleman J, Grubbs R, Andriole G, Tator RE, et al. Final results of a phase I/II multicenter trial of WST11 vascular targeted photodynamic therapy for hemi-ablation of the prostate in men with unilateral low risk prostate cancer performed in the United States. *J Urol* 2016;196:1096–104.
41. Forsyth TP, Narco DJ, Pandey RK, Smith KM. Synthesis and structure of a 5,15-bis(4-pyridyl)porphin. *Tetrahedron Lett* 1995;36:9003–6.
42. De Moraes M, De Vasconcelos RC, Longo JPF, Muehlmann LA, De Azevedo RB, Lemos TM, et al. Effects of photodynamic therapy mediated by nemonemulsion containing chloro-aluminum phthalocyanine: a histologic and immunohistochemical study in human gingiva. *Photodiagn Photodyn Ther* 2015;12:592–7.
43. Muehlmann LA, Rodrigues MC, Longo JPF, Garcia MP, Py-Daniel KR, Veloso AB, et al. Aluminum-phthalocyanine chloride noemulsion for anticancer photodynamic therapy: development and in vitro activity against monolayers and spheroids of human mammary adenocarcinoma MCF-7 cells. *J Nanobiotechnol* 2015;13:36.
44. Miller JD, Baron ED, Scull H, Hsia A, Berlin JC, McCormick T, et al. Photodynamic therapy with the phthalocyanine photosensitize Pe 4: the case experience with preclinical mechanistic and early clinical-translational studies. *Toxicol Appl Pharmacol* 2007;224:290–9.
45. Borgatti-Jeffreys A, Hooser SB, Miller MA, Thomas RM, De Gortari A, Lucroy MD. Preclinical evaluation of zinc phthalocyanine tetrasulfonate-based PDT. *Proc SPIE* 2006;5986:624–30.
46. Wainwright M. Photodynamic therapy: the development of new photosensitisers. *Anti-Cancer Agents Med Chem* 2008;8:280–91.
47. Biel MA. Photodynamic therapy of head and neck cancers. In: Gomer C, editor. *Photodynamic Therapy. Methods in Molecular Biology*. Totowa, NJ: Humana Press; 2010.
48. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. *J Photochem Photobiol B Biol* 1990;6:143–8.
49. Ormond AB, Freeman AB. Dye sensitizers for photodynamic therapy. *Materials* 2013;6:817–40.
50. Tardivo JP, Del Gligio A, De Oliveira CS, Gabrielli DS, Junqueira HC, Tada DB, et al. Methylene blue in photodynamic therapy: from basic mechanisms to clinical applications. *Photodiagn Photodyn Ther* 2005;2:175–91.
51. Graciano TB, Coutinho TS, Cressoni CB, de Paula Freitas C, Pierre MBR, De Lima Pereira SA, et al. Using chitosan gels as a toluidine blue O delivery system for photodynamic therapy of buccal cancer: in vitro and in vivo studies. *Photodiagn Photodyn Ther* 2015;12:98–107.
52. Harris F, Chatfield LK, Phoenix DA. Phenothiazinium based photosensitisers-photodynamic agents with a multiplicity of cellular targets and clinical applications. *Curr Drug Targets* 2005;6:615–27.
53. Harris F, Sayed Z, Hussain S, Phoenix DA. An investigation into the potential of phenothiazinium-based photo-sensitizers to act as PDT agents. *Photodiagn Photodyn Ther* 2004;1:231–9.
54. Cincotta L, Foley JW, Cincotta AH. Photo toxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells. *Cancer Res* 1993;53:2571–80.
55. Cincotta L, Foley JW, MacEachern T, Lampros E, Cincotta AH. Novel photodynamic effects of a benzophenoxazine on two different murine sarcomas. *Cancer Res* 1994;54:1249–58.
56. Delaey E, Van Laar F, De Vos D, Kamuhawba A, Jacobs P, De Witte P. A comparative study of the photosensitizing characteristics of some cyanine dyes. *J Photochem Photobiol B Biol* 2000;55:27–36.
57. Atzpodien J, Gulati SC, Clarkson BD. Comparison of the cytotoxic effects of merocyanine-540 on leukemic cells and normal human bone marrow. *Cancer Res* 1986;46:4892–5.
58. Awuah SG, You Y. Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy. *RSC Adv* 2012;2:9689–83.
59. Lim SH, Thivierge C, Nowak-Sliwinska P, Han JY, Van Den Bergh HC, Tada DA, et al. Methylene blue in photodynamic therapy: from basic mechanisms to clinical applications. *Photodiagn Photodyn Ther* 2005;2:175–91.
60. Kitano GM. Hypericin and pseudohypericin in some Hypericum species. *Biochem Syst Ecol* 2001;29:171–8.
61. Kubin A, Wierani F, Bumer U, Alth G, Grünberger W. Hypericin—the facts about a controversial agent. *Curr Pharm Des* 2005;11:233–53.
62. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. *Cancer Immunol Immunother* 2012;61:215–21.
63. Panchanini E, Inguscio V, Finna GM, Dini L. Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPS) in human HeLa cells. *PLoS One* 2014;9:e0105778.
64. Pandey RK, Herman CK. Shedding some light on tumours. *Chem Ind* 1998;18:739–43.
65. O’Conner AE, Gallagher WM, Byrne AT. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. *Photochem Photobiol* 2009;85:1053–74.
66. Yoon I, Li JZ, Shim YK. Advance in photosensitizers and light delivery for photodynamic therapy. *Clin Endosc* 2003;46:7–23.
Review on new photosensitizers for anticancer photodynamic therapy

67. Garland MJ, Cassidy CM, Woolfson D, Donnelly RF. Designing photosensitizers for photodynamic therapy: strategies, challenges and promising developments. *Future Med Chem* 2009;1:667–91.

68. Fernandez JM, Bilgin MD, Grossweiner LI. Singlet oxygen generation by photosensitizing agents. *J Photochem Photobiol B Biol* 1997;37:131–40.

69. Xodo LE, Cogoi S, Rapozzi V. Photosensitizers binding to nucleic acids as anticancer agents. *Future Med Chem* 2016;8:179–94.

70. Rajendran M. Quinones as photosensitizer for photodynamic therapy: ros generation, mechanism and detection methods. *Photodiagn Photodyn Ther* 2016;13:175–87.

71. Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. *Biochem J* 2016;473:347–64.

72. Li JW, Wu ZM, Magetic D, Zhang LJ, Chen ZL. Antitumor effects evaluation of a novel porphyrin derivative in photodynamic therapy. *Tumour Biol* 2015;36:9685–92.

73. Liao PY, Wang XR, Gao YH, Zhang XH, Zhang LJ, Song CH, et al. Synthesis, photophysical properties and biological evaluation of β-alkylaminoporphyrin for photodynamic therapy. *Bioorg Med Chem* 2016;24:6040–7.

74. Chen JJ, Hong G, Gao LJ, Liu TJ, Cao WJ. Synthesis of unsymmetrical phthalocyanine derivatives and their rhenium(I) conjugates. *J Photochem Photobiol B* 2016;161:943–8.

75. Silva AR, Simioni AR, Tedesco AC. Photophysical and complexation studies of chloro-aluminum phthalocyanine with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. *J Nanosci Nanotechnol* 2011;11:4046–55.

76. Durmus M, Yaman H, Göl C, Ahsen V, Hyokong T. Water-soluble quaternized mercaptopyrrole-substituted zinc-phthalocyanines: synthesis, photophysical and biochemical ovalbumin binding properties. *Dyes Pigm* 2011;91:153–63.

77. Majado MM, Rajaputra P, Nkepang G, You Y. Far-red light activatable, fluorinated chlorin cacy. *J Porphyrins Phthalocyanines* 2013;17:1173–82.

78. Costa LD, Silva Jde A E, Fonseca SM, Arranja CT, Urbanio AM, Sobral AJ. Photophysical characterization and in vitro phototoxicity evaluation of 5,10,15,20-tetraquinolin-2-yl)porphyrin as a potential sensitizer for photodynamic therapy. *Molecules* 2016;21:439.

79. Horuchi H, Hosaka M, Mashio H, Terata M, Ishida S, Kyushin S, et al. Silylation improves the photodynamic activity of tetraphenylporphyrin derivatives in vitro and in vivo. *Chemistry* 2014;20:6054–60.

80. Brunner H, Obermeier H, Platinum(II) complexes with porphyrin ligands-additive cytotoxic and photodynamic effect. *Angew Chem Int Engl* 1994;33:2214–5.

81. Mien G, Gianferrara T, Bergamo A, Gasser G, Pierroz V, Rubbiani R, et al. Phototoxic activity and DNA interactions of water-soluble porphyrins and their rhenium(I) conjugates. *ChemMedChem* 2015;10:1901–14.

82. Meng Z, Yu B, Han GY, Liu MH, Shan B, Dong GQ, et al. Chlorin P₈-based water-soluble amino acid derivatives as potent photosensitizers for photodynamic therapy. *J Med Chem* 2016;59:4999–5010.

83. Jinadasa RGW, Zhou ZH, Vicente MG, Smith KM, Syntheses and cellular investigations of di-aspartate and aspartate-lysine chlorin ε₂ conjugates. *Org Biomol Chem* 2016;14:1049–64.

84. Narumi A, Tsujii T, Shinohara K, Yamazaki H, Kiduki M, Kawaguchi S, et al. Maltotriose-conjugation to a fluorinated chlorin derivative generating a PDT photosensitizer with improved water-solubility. *Org Biomol Chem* 2016;14:5608–13.

85. Kahl SB, Koo M-S. Synthesis of tetras-carboxylcarboxylate esters of 2,4-bis(α,β-dihydroxyethyl)-deuteroporphyrin IX. *J Chem Soc Chem Commun* 1990;0:1769–71.

86. Asano R, Nagami A, Fukumoto Y, Miura K, Yazama F, Ito H, et al. Synthesis and biological evaluation of new boron-containing chlorin derivatives as agents for both photodynamic therapy and boron neutron capture therapy of cancer. *Bioorg Med Chem Lett* 2014;24:1539–43.

87. Patel N, Pera P, Joshi P, Dukh M, Tabaczynski WA, Sieres KE, et al. Highly effective dual-function near-infrared (NIR) photosensitizer for fluorescence imaging and photodynamic therapy (PDT) of cancer. *J Med Chem* 2016;59:9734–87.

88. Arslanoğlu Y, Nyokong T. Synthesis and photophysical studies of mono-carboxy phthalocyanines containing quaternizable groups. *Polyhedron* 2013;30:2733–9.

89. de Oliveira KT, De Assis FF, Ribeiro AO, Neri CR, Fernandes AU, Baptista MS, et al. Synthesis of phthalocyanines–ALA conjugates: water-soluble compounds with low aggregation. *J Org Chem* 2009;74:7962–5.

90. Do Nascimento FB, manieri TM, Cerchiaro G, Ribeiro AO. Synthesis of unsymmetrical phthalocyanine derivatives and their interaction with mammery MCF7 cells. *Dyes Pigm* 2013;99:316–22.

91. Kucinska M, Skupin-Mrugalska P, Szczolko W, Bobolta L, Sciepura J, Tykarska E, et al. Phthalocyanine derivatives possessing 2-(morpholin-4-yl)ethoxy groups as potential agents for photodynamic therapy. *J Med Chem* 2015;58:2240–55.

92. Wierczowski M, Sobol L, Skupin-Mugalska P, Kruk J, Jasiak W, Yee M, et al. Phthalocyanines functionalized with 2-methyl-5-nitro-1H-imidazolol ethoxycarboxylic acid and the effect of metformin on phototoxicity. *J Inorg Biochem* 2013;127:62–72.

93. Zhou XQ, Meng LB, Huang Q, Li J, Zheng K, Zhang FL, et al. Synthesis and in vitro anticancer activity of zinc(II) phthalocyanines conjugated with coumarin derivatives for dual photodynamic and chemotheraphy. *ChemMedChem* 2015;10:304–11.

94. Jia X, Yang FF, Li J, Liu JY, Xue JP. Synthesis and in vitro photodynamic activity of oligomeric ethylene glycol-quinoline substituted zinc(II) phthalocyanines derivatives. *J Med Chem* 2013;56:7597–805.

95. Ranyuk E, Cauchoin N, Klanovsk K, Guérin B, Van Liejer JE. Phthalocyanine-peptide conjugates: receptor-targeting bifunctional agents for imaging and photodynamic therapy. *J Med Chem* 2013;56:1520–34.

96. Machacek M, Cidlina A, Novakova V, Svec J, Rudolf E, Miletin M, et al. Far-red-absorbing cationic phthalocyanine photosensitizers: synthesis and evaluation of the photodynamic anticancer activity and the mode of cell death induction. *J Med Chem* 2015;58:1736–49.

97. Shen XM, Zheng BY, Huang XR, Wang L, Huang JD. The first silicon(IV) phthalocyanine-nucleoside conjugates with high photodynamic activity. *Dalton Trans* 2013;42:10398–403.

98. Moli M, Rajaputra P, Nkepang G, You Y. Far-red light activatable, multifunctional prodrug for fluorescence optical imaging and combinational treatment. *J Med Chem* 2014;57:3401–9.

99. Erbas-Cakmak S, Cakmak FP, Topel SD, Uyar TB, Atkaya EU. Selective photosensitization through an AND logic response: optimization of the pH and glutathione response of activatable photosensitizers. *Chem Commun (Camb)* 2015;51:12258–61.

100. Jiang XJ, Lau JT, Wang Q, Ng DK, Lo PC, pH- and thiol-responsive BODIPY-based photosensitizers for targeted photodynamic therapy. *Chemistry* 2016;22:8273–81.
104. Mitra K, Gautam S, Kondaiah P, Chakravarty AR. BODIPY-appended 2-(2-pyridyl)benzimidazole platinum(II) catecholates for mitochondria-targeted photocytotoxicity. *ChemMedChem* 2016;11:1956–67.

105. Fraix A, Blangetti M, Guglielmo S, Lazzarato L, Marino N, Cardile V, et al. Light-tunable generation of singlet oxygen and nitric oxide with a bichromophoric molecular hybrid: a bimodal approach to killing cancer cells. *ChemMedChem* 2016;11:1371–9.

106. Lincoln R, Durantini AM, Greene LE, Martínez SR, Knox R, Becerra MC, et al. meso-Acetoxymethyl BODIPY dyes for photodynamic therapy: improved photostability of singlet oxygen photosensitizers. *Photochem Photobiol Sci* 2016;16:178–84.

107. Ozdemir T, Bila JL, Sozmen F, Yildirim LT, Akkaya EU. Orthogonal bodipy trimers as photosensitizers for photodynamic action. *Org Lett* 2016;18:4821–3.